Recent Updates
Recently added Catalysts
WHWK Positive Sentiment

Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Wednesday, November 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Whitehawk Therapeutics, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. CEO Dave Lennon will lead a fireside discussion, which will also be available via live webcast. The company focuses on advanced antibody drug conjugate therapies for challenging cancers.
Price reaction · baseline $2.15 (2025-11-25 close) · hit pre-market · 1 other WHWK headline(s) in the window, move may be shared
day 0 close
+7%
day 1 · peak
+8.8%
day 3
+1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent healthcare conference highlights company visibility.
  • Fireside chat format allows for engaging discussions on oncology advancements.
  • Showcases Whitehawk's commitment to improving cancer treatment options.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~38 mo
Minimal dilution risk
Lead asset
HWK-016, MUCIN-16-targeted ADC
Phase 1 · PROC

Full Press Release Details

MORRISTOWN, N.J.,Nov. 26, 2025/PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City, NY on December 3, 2025, at 12:30 PM ET.
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IRwebsiteand will be available for replay for approximately 30 days following the event.

About Whitehawk TherapeuticsWhitehawkTherapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments.Whitehawk'sadvanced three-assetADCportfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed fromWuXiBiologics under an exclusive development and global commercialization agreement. More information on the Company is available atwww.whitehawktx.comand connect with us on LinkedIn.

Contact:[email protected]

Frequently Asked Questions

When will Whitehawk Therapeutics participate in the conference?

Whitehawk Therapeutics will participate in the conference on December 3, 2025.

Who will represent Whitehawk Therapeutics at the conference?

Dave Lennon, PhD, President and CEO, will represent Whitehawk Therapeutics.

How can I access the conference discussion?

The discussion can be accessed via a live webcast on the Whitehawk Therapeutics IR website.

What is the focus of Whitehawk Therapeutics?

Whitehawk Therapeutics focuses on advanced oncology therapeutics and antibody drug conjugates.

ShareAdd on Google
Tags: WHWK Viatris Investor Conferences Healthcare Whitehawk Therapeutics Piper Sandler oncology cancer treatments Dave Lennon
Last updated: Nov 26, 2025

Biotech snapshot

Cash runway
$190M liquidity · $5M/mo burn
~38 mo
Minimal dilution risk
Lead asset
HWK-016, MUCIN-16-targeted ADCPhase 1
PROC →